HMSE:SAZ

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

STADA Arzneimittel Aktiengesellschaft engages in the health care and pharmaceuticals business worldwide. More Details


Snowflake Analysis

Imperfect balance sheet with poor track record.


Similar Companies

Share Price & News

How has STADA Arzneimittel's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SAZ is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 1% a week.

Volatility Over Time: SAZ's weekly volatility (1%) has been stable over the past year.


Market Performance


7 Day Return

0%

SAZ

-0.4%

DE Pharmaceuticals

0.5%

DE Market


1 Year Return

n/a

SAZ

-5.2%

DE Pharmaceuticals

2.2%

DE Market

Return vs Industry: Insufficient data to determine how SAZ performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how SAZ performed against the German Market.


Shareholder returns

SAZIndustryMarket
7 Day0%-0.4%0.5%
30 Day0%4.2%7.9%
90 Day1.0%3.0%4.6%
1 Yearn/a-2.2%-5.2%5.5%2.2%
3 Yearn/a26.9%12.2%4.4%-4.7%
5 Yearn/a29.7%7.7%30.5%12.2%

Long-Term Price Volatility Vs. Market

How volatile is STADA Arzneimittel's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is STADA Arzneimittel undervalued compared to its fair value and its price relative to the market?

25.12x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: SAZ (€102) is trading above our estimate of fair value (€60.82)

Significantly Below Fair Value: SAZ is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SAZ is poor value based on its PE Ratio (25.1x) compared to the XE Pharmaceuticals industry average (23.7x).

PE vs Market: SAZ is poor value based on its PE Ratio (25.1x) compared to the German market (22.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SAZ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SAZ's PB Ratio (6.2x) is in line with the DE Pharmaceuticals industry average.


Next Steps

Future Growth

How is STADA Arzneimittel forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

33.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as STADA Arzneimittel has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has STADA Arzneimittel performed over the past 5 years?

30.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SAZ has a large one-off loss of €97.0M impacting its June 30 2020 financial results.

Growing Profit Margin: SAZ's current net profit margins (9%) are lower than last year (11.4%).


Past Earnings Growth Analysis

Earnings Trend: SAZ's earnings have grown significantly by 30.8% per year over the past 5 years.

Accelerating Growth: SAZ's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SAZ had negative earnings growth (-9.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (13.2%).


Return on Equity

High ROE: Whilst SAZ's Return on Equity (23.86%) is high, this metric is skewed due to their high level of debt.


Next Steps

Financial Health

How is STADA Arzneimittel's financial position?


Financial Position Analysis

Short Term Liabilities: SAZ's short term assets (€2.0B) exceed its short term liabilities (€1.3B).

Long Term Liabilities: SAZ's short term assets (€2.0B) do not cover its long term liabilities (€2.7B).


Debt to Equity History and Analysis

Debt Level: SAZ's debt to equity ratio (255.6%) is considered high.

Reducing Debt: SAZ's debt to equity ratio has increased from 143.5% to 255.6% over the past 5 years.

Debt Coverage: SAZ's debt is not well covered by operating cash flow (16.6%).

Interest Coverage: SAZ's interest payments on its debt are well covered by EBIT (6.9x coverage).


Balance Sheet


Next Steps

Dividend

What is STADA Arzneimittel current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SAZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SAZ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SAZ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SAZ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SAZ's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Peter Goldschmidt (56 yo)

2.17yrs

Tenure

€1,248,000

Compensation

Mr. Peter Goldschmidt serves as the President of Sandoz Inc. Mr. Goldschmidt serves as Head of North American Operations at Sandoz International GmbH and has been its President of Sandoz US since July 2013...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD0.00) is below average for companies of similar size in the German market ($USD3.86M).

Compensation vs Earnings: Insufficient data to compare Peter's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Peter Goldschmidt
Chairman of the Executive Board & CEO2.17yrs€1.25mno data
Miguel Fernandez
CTO & Member of Executive Board2.33yrs€704.00kno data
Wolfgang Ollig
Group Chief Financial Officer & Member of Executive Board0.75yrno datano data
Christoph Dengler
Executive Vice President of Global Legalno datano datano data
Frank Staud
Executive Vice President of Global Communications & Brandingno datano datano data
Simone Berger
Executive Vice President of Global Human Resources1.83yrsno datano data
Carsten Cron
Executive Vice President of Emerging Markets2.5yrsno datano data
Eelco Ockers
Executive Vice President of Germany1.17yrsno datano data
Roger Scarlett-Smith
Executive Vice President UK & USno datano datano data
Steffen Wagner
Executive Vice President of European Marketsno datano datano data
Stephan Eder
Executive Vice President of Russia & CIS0.42yrno datano data
Yann Brun
Executive VP & Head of Global Development0.83yrno datano data

1.5yrs

Average Tenure

55.5yo

Average Age

Experienced Management: SAZ's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Michael Siefke
Member of Supervisory Board3.17yrsno datano data
Günter von Au
Chairman of Supervisory Board3.17yrs€304.02kno data
Thomas Meyer
Chairman of Advisory Boardno datano datano data
Frank-R. Leu
Deputy Chairman of Advisory Boardno datano datano data
Rika Aschenbrenner
Member of Advisory Boardno datano datano data
Wolfgang Schlags
Member of Advisory Boardno datano datano data
Reimar von Kolczynski
Member of Advisory Boardno datano datano data
Jan-Nicolas Garbe
Member of Supervisory Board3.17yrsno datano data
Benjamin Kunstler
Member of Supervisory Board3.17yrsno datano data
Jens Steegers
Employee Representative Member of Supervisory Board6.83yrs€193.40kno data
Eric Cornut
Member of Supervisory Board4.83yrs€92.41kno data
Markus Damm
Employee Representative Deputy Chairman1.5yrsno datano data

3.2yrs

Average Tenure

53yo

Average Age

Experienced Board: SAZ's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

STADA Arzneimittel Aktiengesellschaft's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: STADA Arzneimittel Aktiengesellschaft
  • Ticker: SAZ
  • Exchange: HMSE
  • Founded: 1895
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €6.350b
  • Shares outstanding: 62.26m
  • Website: https://www.stada.de

Number of Employees


Location

  • STADA Arzneimittel Aktiengesellschaft
  • Stadastrasse 2-18
  • Bad Vilbel
  • 61118
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
0OM4LSE (London Stock Exchange)YesCommon SharesGBEURFeb 1998
SAZHMSE (Hamburg Stock Exchange)YesCommon SharesDEEURFeb 1998
STDA.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDDec 2008

Biography

STADA Arzneimittel Aktiengesellschaft engages in the health care and pharmaceuticals business worldwide. The company operates in two segments, Generics and Branded Products. The Generics segment provides v...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/21 19:52
End of Day Share Price2020/11/09 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.